Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- EU5

Publisher Name :
Date: 01-Nov-2016
No. of pages: 60
This report is available at upto 40% Discount. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023-EU5" report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023).

GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight's estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.71% from 2013-2023 and reach up to 30,328 cases in the year 2023.

The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per DelveInsight forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 3.96% and 4.05%, respectively, from 2013-2023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 4.05% and 4.04%, respectively, by the end of the year 2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

- Report covers the disease overview including pathophysiology, symptoms, diagnosis and disease management.

- It focuses on the risk factors and the historical trends of the diagnosed incident cases of allogeneic Hematopoietic Stem Cell Transplants (HSCTs) ( which also includes the cases of first transplants along with the total transplants)

- The Report also covers the detailed historical and forecasted number of diagnosed incident cases of acute GVHD and chronic GVHD, segmented by the type of donors (Sibling donors and unrelated donors) for the EU5 countries(Germany, France, Italy, Spain and United Kingdom) from 2013-2023.

Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- EU5

Table of Contents

Graft Versus Host Disease (GVHD)
Disease Definition
Disease Types
Acute GvHD
Chronic GvHD
Grades of GvHD
Pathophysiology
Risk Factors for GVHD
Diagnosis
Epidemiology and Patient Population
Key Points
Germany
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
France
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Spain
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Italy
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
United Kingdom
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Assumptions and Rationale
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List of Tables

Table 1: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Table 2: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 3: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 4: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Table 5: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 6: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 7: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Table 8: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 9: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 10: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Table 11: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 12: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 13: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Table 14: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Table 15: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)

List of Figures

Figure 1: Pathophysiology of GvHD
Figure 2: Risk Factors for GvHD
Figure 3: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Figure 4: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Figure 5: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Figure 6: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Figure 7: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Figure 8: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Figure 9: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Figure 10: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Figure 11: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Figure 12: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Figure 13: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Figure 14: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Figure 15: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Figure 15: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Figure 16: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
  • Global Buprenorphine Hydrochloride Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 02-Dec-2016        Price: US 3480 Onwards        Pages: 113
    Buprenorphine hydrochloride, a white crystalline powder, is a semisynthetic opioid analgesic used for the relief of moderate to severe pain. It is in the same chemical family of morphine, codeine and heroin. However, buprenorphine hydrochloride has the distinction of producing less euphoric effects than those drugs. Scope of the Report: This report focuses on the Buprenorphine Hydrochloride in Global market, especially in North America, Europe and Asia-Pacific, South Americ......
  • United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022
    Published: 01-Dec-2016        Price: US 1000 Onwards        Pages: 122
    United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and s......
  • Europe Meningococcal Vaccines Market Report 2016
    Published: 01-Dec-2016        Price: US 3900 Onwards        Pages: 100
    Notes: Sales, means the sales volume of Meningococcal Vaccines Revenue, means the sales value of Meningococcal Vaccines This report studies sales (consumption) of Meningococcal Vaccines in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - GlaxoSmithKline - Sanofi Pasteur - Merck......
  • Global Human Immunoglobulin Sales Market Report 2020
    Published: 01-Dec-2016        Price: US 4000 Onwards        Pages: 125
    This report studies sales (consumption) of Human Immunoglobulin in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Baxter - CSL - Grifols - Octapharma - Biotest - China National Pharmaceutical Group - CTBB - Hualan Bio - RAAS - Shanxi Kangbao Bio......
  • United States Antibodies Market Report 2016
    Published: 01-Dec-2016        Price: US 3800 Onwards        Pages: 105
    Notes: Sales, means the sales volume of Antibodies Revenue, means the sales value of Antibodies This report studies sales (consumption) of Antibodies in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - ABCAM - ABNOVA - ABD SEROTEC (BIO-RAD) - ACTIVE MOTIF - BD BIOSCIENCES - BECKMAN COULTER - BETHYL LABORATORIES - BIOLEGEND - BIO-TECH......
  • Europe Inhalation & Nasal Spray Generic Drugs Market Report 2016
    Published: 01-Dec-2016        Price: US 3900 Onwards        Pages: 101
    Notes: Sales, means the sales volume of Inhalation & Nasal Spray Generic Drugs Revenue, means the sales value of Inhalation & Nasal Spray Generic Drugs This report studies sales (consumption) of Inhalation & Nasal Spray Generic Drugs in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Teva......
  • Global Budesonide Sales Market Report 2016
    Published: 01-Dec-2016        Price: US 4000 Onwards        Pages: 101
    Notes: Sales, means the sales volume of Budesonide Revenue, means the sales value of Budesonide This report studies sales (consumption) of Budesonide in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Sanofi - GlaxoSmithKline - Pfizer - Johnson & Johnson - ... Market Seg......
  • Global Metabolism Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 01-Dec-2016        Price: US 3480 Onwards        Pages: 116
    Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.Scope of the Report:This report focuses on the Metabolism Drugs in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.......
  • United States Aspirin Market Report 2016
    Published: 01-Dec-2016        Price: US 3800 Onwards        Pages: 101
    Notes: Sales, means the sales volume of Aspirin Revenue, means the sales value of Aspirin This report studies sales (consumption) of Aspirin in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Bayer - Novacap - Shandong Xinhua Pharmaceutical - Nanjing Pharmaceutical Factory - Jilin Pharmaceutical - Zhongnan Pharmaceutical - Jiuming Pharmaceutical......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs